Seeking Alpha

20 out of 26 panelists vote to either ease restrictions or eliminate them entirely on...

20 out of 26 panelists vote to either ease restrictions or eliminate them entirely on GlaxoSmithKline's (GSK) diabetes treatment Avandia after a two-day meeting at which FDA officials considered the results of a Duke University study which reportedly supports GSK's contention that heart worries surrounding the drug may be overblown.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|